Read or download the official PDF of this gazette notification issued by the Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals on 8th August 2026. Classified under Press Release.
Executive Summary
Union Minister Shri Jagat Prakash Nadda chaired a CEO Roundtable during the "India Medical Device 2026" event on 08 August 2026 to discuss the future of India’s MedTech sector. The meeting focused on strengthening the medical device ecosystem through innovation, domestic manufacturing, and global expansion. Key outcomes emphasized the necessity of evidence-based decision-making and sustainable reimbursement mechanisms to ensure affordable and accessible healthcare.
Key Points / Main Content
Strategic Objectives for the MedTech Sector
Ecosystem Strengthening: High-level dialogue focused on promoting investment and enhancing domestic manufacturing capabilities.
Global Expansion: Creating an enabling environment for Indian medical device companies to increase their international footprint.
Collaborative Governance: The event brought together over 40 CEOs from global and domestic companies, MSMEs, and senior policymakers from various government departments.
Reimbursement and Healthcare Access
Universal Health Coverage (UHC): Discussions highlighted the role of innovative therapies in achieving UHC through affordable and sustainable healthcare solutions.
Economic Assessment: High-quality evidence on clinical effectiveness is deemed essential for meaningful health-economic assessments and cost-effectiveness evaluations.
Sustainable Balancing: The goal is to develop a reimbursement ecosystem that balances access to new technologies with fiscal sustainability and affordability.
Evidence and Regulatory Requirements
Clinical Evidence: Robust clinical data must underpin all regulatory, reimbursement, and procurement decisions.
Value Demonstration: Innovative technologies must demonstrate clinical value through evidence-based approaches to improve patient outcomes.
HTA Compliance: Seeking exemptions from evidence generation is discouraged, as it hinders the ability of technologies to establish value before Health Technology Assessment (HTA) authorities.
Framework for Adoption
Transparent Processes: Wider adoption of medical technologies requires transparent HTA processes and realistic pricing.
System Improvements: Enhancing the sector requires greater clinician participation and the implementation of stronger training systems.
Impact Analysis
MedTech Companies (Global, Domestic, and MSMEs)Impact
Companies are expected to align their innovation strategies with high standards of clinical evidence and cost-effectiveness to secure regulatory and reimbursement approvals.
Action Required
Focus on generating credible clinical evidence and avoid seeking exemptions from evidence generation to successfully navigate HTA and procurement authorities.
Government and Regulatory Bodies (Department of Pharmaceuticals, ICMR, NITI Aayog)Impact
These bodies are responsible for establishing the frameworks that govern the medical device market, including HTA processes and reimbursement mechanisms.
Action Required
Develop and implement transparent HTA processes, sustainable reimbursement mechanisms, and evidence-based decision-making frameworks.
Healthcare Providers and CliniciansImpact
The sector aims for higher clinician involvement in the evaluation and adoption of new medical technologies.
Action Required
Increase participation in clinical evaluations and engage with new training systems to support the adoption of innovative medical technologies.
Key Entities Referenced
India Medical Device 2026: The flagship event and platform for high-level dialogue on strengthening India’s medical device ecosystem and enhancing domestic manufacturing capabilities.
Shri Jagat Prakash Nadda: Union Minister of Chemicals & Fertilizers and Health & Family Welfare who chaired the CEO Roundtable to deliberate on the future of India’s MedTech sector.
Department of Pharmaceuticals: The primary government department responsible for organizing the event and overseeing the growth and regulation of the medical device industry in India.
Health Technology Assessment (HTA): A critical framework and process discussed for evaluating the clinical effectiveness and cost-effectiveness of innovative medical technologies to determine reimbursement.
Federation of Indian Chambers of Commerce & Industry (FICCI): The industry association that co-organized the roundtable, representing global and domestic MedTech companies and MSMEs.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Union Minister Shri Jagat Prakash Nadda Chairs
CEO Roundtable at India Medical Device 2026
प्रव तथ: 08 AUG 2026 5:54PM by PIB Delhi
Union Minister of Chemicals & Fertilizers and Health & Family Welfare Shri Jagat Prakash Nadda
addressed the CEO Roundtable on the second day of India Medical Device 2026, organised by the
Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, in association
with the Federation of Indian Chambers of Commerce & Industry (FICCI), at Vigyan Bhawan, New Delhi
The Roundtable brought together senior policymakers and leaders of the medical device industry to
deliberate on the future of India’s MedTech sector. It was attended by Shri Manoj Joshi, Secretary,
Department of Pharmaceuticals; Dr. M Srinivas, Member, NITI Aayog; Dr. Rajiv Bahl, Secretary,
Department of Health Research & Director General, ICMR; Smt. Punya Salila Srivastava, Secretary,
Department of Health and Family Welfare; Shri Amardeep Singh Bhatia, Secretary, Department of
Promotion of Industry & Internal Trade (DPIIT); Shri Sunil Kumar Barnwal, CEO, National Health
Authority, Shri Anant Swarup, Secretary General, FICCI; Shri Tushar Sharma, Chair, FICCI Medical
Devices Committee; Shri Himanshu Baid, Co-Chair, FICCI Medical Devices Committee; Shri
Bharath Sesha, Co-Chair, FICCI Medical Devices Committee. More then 40 CEOs of global, domestic
MedTech companies and MSMEs participated in the RoundTableThe CEO Roundtable provided a platform for high-level dialogue on strengthening India’s medical
device ecosystem, promoting innovation and investment, enhancing domestic manufacturing
capabilities and enabling the environment for Indian medical device companies to expand their global
footprint.
Earlier in the day, Dr Rajiv Bahl, Secretary, Department of Health Research and Director General,
Indian Council of Medical Research (ICMR), Government of India, chairing a session on
“Reimbursement Mechanisms for Innovative Therapies in India’s Path to Universal Health
Coverage (UHC)” highlighted the importance of strengthening evidence-based decision-making. He said
medical innovations should translate into affordable, accessible and sustainable healthcare.Dr Bahl emphasised that robust clinical evidence should underpin regulatory, reimbursement and
procurement decisions. He noted that evidence-based approaches are essential to ensure that innovative
technologies demonstrate their clinical value and contribute meaningfully to improved patient outcomes.
He further stressed that high-quality evidence on clinical effectiveness is essential for meaningful cost-
effectiveness and health-economic assessment. He cautioned that seeking exemptions from evidence
generation may make it difficult for technologies to establish their value before Health Technology
Assessment (HTA), reimbursement and procurement authorities.
Participants highlighted the need for a framework that can support the adoption of new medical
technologies while ensuring that healthcare resources are utilised effectively. The session underscored that
wider adoption of innovative medical technologies in India will require credible clinical evidence,
transparent HTA processes, realistic pricing, sustainable reimbursement mechanisms, greater
clinician participation and stronger training systems. The discussion focused on developing a
reimbursement ecosystem that balances access to innovative technologies with affordability and fiscal
sustainability.
*****
PC/PM
(रलीज़ आईडी: 2296571) आगंतुक पटल : 694
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Gujarati , Tamil